OncoMatch/Clinical Trials/NCT06777316
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
Is NCT06777316 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies CGT4859 for intrahepatic cholangiocarcinoma (icc).
Treatment: CGT4859 — This is an open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4859 in adult participants with intrahepatic cholangiocarcinoma (iCCA) or other advanced solid tumors with FGFR2 and/or FGFR3 genetic alternations.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cholangiocarcinoma
Tumor Agnostic
Biomarker criteria
Required: FGFR2 fusion
documented FGFR2/3 alteration in blood and/or tumor
Required: FGFR2 rearrangement
documented FGFR2/3 alteration in blood and/or tumor
Required: FGFR2 amplification
documented FGFR2/3 alteration in blood and/or tumor
Required: FGFR2 short variant
documented FGFR2/3 alteration in blood and/or tumor
Required: FGFR3 fusion
documented FGFR2/3 alteration in blood and/or tumor
Required: FGFR3 rearrangement
documented FGFR2/3 alteration in blood and/or tumor
Required: FGFR3 amplification
documented FGFR2/3 alteration in blood and/or tumor
Required: FGFR3 short variant
documented FGFR2/3 alteration in blood and/or tumor
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard-of-care first-line treatment
Previously treated with, not appropriate for, or declined standard-of-care first-line treatment
Cannot have received: FGFR inhibitor
Exception: no more than 2 prior FGFRi therapies allowed
Received more than 2 prior FGFRi therapies
Lab requirements
Blood counts
clinically acceptable local laboratory screening results (clinical chemistry and hematology) within certain limits
Kidney function
clinically acceptable local laboratory screening results (clinical chemistry and hematology) within certain limits
Liver function
clinically acceptable local laboratory screening results (clinical chemistry and hematology) within certain limits
clinically acceptable local laboratory screening results (clinical chemistry and hematology) within certain limits
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Mayo Clinic Scottsdale · Scottsdale, Arizona
- Stanford Cancer Institute · Palo Alto, California
- Mayo Clinic Jacksonville · Jacksonville, Florida
- Moffitt Cancer Center · Tampa, Florida
- University of Chicago Medicine Comprehensive Cancer Center · Chicago, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify